Vexa

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vexa

Property Description
Active Ingredients Drospirenone and Ethinyl Estradiol
Form Oral Tablet
Pharmacological Class Progestogens and Estrogens in combination
Common Use Pregnancy Prevention (Contraception)
Origin Synthetic Hormones

Vexa is a prescription-only medication classified as a Combined Oral Contraceptive (COC), primarily utilized for pregnancy prevention in women of reproductive age. This medication is taken by the oral tablet route of administration and relies on a dual-hormone blend of synthetic compounds. Its specific formulation, containing Drospirenone and Ethinyl Estradiol, is well-known, with other brand-name products also utilizing this identical combination.


What Type of Medicine is Vexa?

Vexa belongs to the pharmacological class of Progestogens and Estrogens in combination for systemic use, which is the standard classification for this type of hormonal birth control. The medication is entirely synthetic in origin, designed to provide consistent hormonal signals to the body. Its use for birth control is clinically recognized for its high efficacy when taken correctly.


Vexa's Composition: Drospirenone and Ethinyl Estradiol

The core of Vexa is the blend of its two active ingredients: the progestin Drospirenone and the estrogen Ethinyl Estradiol. As a combination product, it uses both hormones to regulate the monthly cycle. Drospirenone is chemically unique among common progestins, possessing antimineralocorticoid and antiandrogenic properties. This confirms that Drospirenone has specific attributes related to hormone regulation that differentiate it from older generation COCs.


What is the General Purpose of Vexa?

The primary purpose of Vexa is to provide highly effective contraception by introducing stable, elevated levels of synthetic hormones into the body. This action achieves Inhibition of Ovulation, which is the main way conception is prevented. The stable hormonal pattern created by Vexa can also address certain predictable, cycle-related concerns for women who choose this method of birth control.

What side effects are possible with Vexa?

Safety Information and Possible Side Effects for Vexa

Vexa's official safety profile, based on regulatory documentation, highlights hepatic transaminase elevation as a key safety concern, leading to required safety monitoring. The most common adverse reactions are generally mild to moderate.

Frequency of Adverse Reactions

Frequency Classification Examples of Affected System Organ Classes
Very Common (ge 1/10) Not applicable based on available common side effect data.
Common (1/10 to 1/100) Gastrointestinal disorders (e.g., diarrhea); Psychiatric disorders (insomnia); Nervous system disorders (e.g., headache); Musculoskeletal disorders (e.g., back pain); General disorders (e.g., hot flush); Investigations (Hepatic transaminase elevation).
Uncommon (ge 1/1,000 to <1/100) No specific examples are listed as uncommon in the core safety summary, as reactions are generally categorized by frequency above 2% or as rare/serious.

Serious Adverse Reactions and Safety Precautions

Serious Adverse Reaction:

  • Hepatotoxicity/Drug-Induced Liver Injury: Post-marketing reports have identified a rare but serious risk of liver injury, characterized by elevations of liver enzymes (ALT/AST) sometimes accompanied by increased total bilirubin and symptoms suggestive of liver impairment (e.g., jaundice, severe fatigue). This has led to the inclusion of a Boxed Warning in official labeling.

Safety Monitoring and Restrictions:

  • Liver Function Monitoring: Liver function tests (ALT/AST) must be performed prior to starting Vexa. Follow-up testing is mandatory, typically monthly for the first three months, and then at six and nine months after initiating therapy.
  • Contraindications: Vexa is formally contraindicated for use in patients with known cirrhosis, severe renal impairment or end-stage renal disease, or for patients taking moderate or strong CYP1A2 inhibitors (which can increase Vexa exposure).
  • Discontinuation Criteria: Treatment must be stopped if liver enzymes (ALT or AST) exceed three to five times the upper limit of normal, particularly if accompanied by elevations in total bilirubin or symptoms of liver injury.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Vexa

Overdose Scope

Documented overdose presentations:

  • Nausea, Vomiting
  • Vaginal bleeding (withdrawal bleeding)

Physiological systems affected:

  • Gastrointestinal system
  • Reproductive system
  • Neurological system

Dose-related or exposure-related factors:

  • Overdose may result from the ingestion of large doses of the medication.

Population-specific overdose notes:

  • None explicitly documented in official regulatory summaries.

Emergency-response statements:

  • Seek emergency medical attention.
  • Call the Poison Help line.
  • Call 911 (or local emergency services).

When immediate medical help is required (label-derived phrasing only):

  • For a suspected overdose.
  • If the individual has trouble breathing, is passing out (unconscious), or has a seizure or collapse.

Overdose Classifications (High-Level)

Severity classification:

  • Severe, life-threatening symptoms require the highest level of emergency action (Call 911).

Regulatory basis:

  • Information is based on FDA Prescribing Information and NIH/MedlinePlus drug summaries.

Overdose-context constraints:

  • Manifestations are limited to those resulting from acute ingestion of doses higher than recommended.

Resulting Overdose Structure

Official overdose statements:

  • Overdose may present with documented nausea, vomiting, and vaginal bleeding.
  • Immediate medical attention must be sought for a suspected overdose.
  • Urgent emergency services (Call 911) are required if the overdose is accompanied by severe symptoms such as seizure, collapse, or loss of consciousness.

Connection to the overall overdose profile: The regulatory documents define the overdose profile by listing specific physical manifestations that may occur after ingesting large doses. The profile’s central focus is on defining the triggers for emergency action, explicitly mandating seeking medical attention and contacting 911 when severe, life-threatening neurological or respiratory symptoms are present.

Therapeutic Uses of Vexa

Vexa is relevant for easing symptoms across several domains in women's health. Its primary application is to assist in pregnancy prevention in women of reproductive potential. It is generally relevant across domains where additional symptomatic support is needed, including the management of Premenstrual Dysphoric Disorder (PMDD) and providing relief for moderate acne vulgaris.

The medication is considered relevant for managing severe, recurring psychological and physical symptoms that often cluster and become more disruptive during flare-ups. Supportive relief in this domain may assist with easing the overall burden of difficult episodes and contribute to improved comfort. Furthermore, Vexa may be relevant for addressing challenging symptoms like severe menstrual cramping (dysmenorrhea) and excessive blood loss (menorrhagia). This symptomatic support may assist with maintaining functional stability and supports general well-being during symptomatic phases.

“This medication is applied in scenarios where additional management of discomfort is required for severe cyclical symptoms.”

Quick Fact: Symptomatic Support for Cyclical Discomfort

Regulatory References

  1. DailyMed official label for Drospirenone and Ethinyl Estradiol

Eligibility and Restrictions for Use

Vexa (Drospirenone and Ethinyl Estradiol) is formally indicated for use by females of reproductive potential. Eligibility is strictly defined by regulatory documents, focusing on patient health status and absence of absolute contraindications.

Populations for Whom Use is Contraindicated

Use is absolutely contraindicated in women with an officially documented high risk of arterial or venous thrombotic diseases, including deep vein thrombosis, pulmonary embolism, stroke, or heart attack. This prohibition formally extends to women over age 35 who smoke.

Contraindications also apply to conditions affecting specific organs due to the Drospirenone component. Vexa must not be used by patients with renal impairment, adrenal insufficiency, or liver tumors/severe liver disease (due to hyperkalemia risk). Current or history of breast cancer is also a formal contraindication.

Age and Physiological Restrictions

The medicine is not indicated for use in elderly women (post-menopause). While use is permitted in adolescents, it must not be started before menarche (the onset of menstruation). Vexa is contraindicated if pregnancy is confirmed and is not recommended for women who are nursing.

What should I know about interactions with other medicines?

Vexa’s interaction profile is shaped by the hormonal components’ metabolism and Drospirenone's specific anti-mineralocorticoid activity, as defined in regulatory documentation.

Contraindicated Combinations

A formal contraindication exists for co-administration with certain Hepatitis C Virus (HCV) drug combinations (specifically those containing Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir) due to the documented risk of significant liver enzyme elevations.

Drug–Drug Interactions and Exposure

Pharmacokinetic interactions center on the CYP3A4 enzyme system. Substances classified as CYP3A4 inducers—including certain anticonvulsants and the herbal product St. John's Wort—are documented to reduce the plasma concentration of Vexa's hormones, risking reduced effectiveness. Conversely, strong CYP3A4 inhibitors (such as specific antifungals or protease inhibitors) may increase the exposure of Drospirenone.

A key pharmacodynamic interaction involves drugs that raise serum potassium levels. Caution is required with agents like Potassium-Sparing Diuretics, ACE Inhibitors, and long-term NSAID use. For individuals on long-term potassium-elevating co-medication, regulatory guidance mandates monitoring of serum potassium concentration during the first treatment cycle. This hyperkalemia risk also makes Vexa contraindicated in females with Renal Impairment or Adrenal Insufficiency.

Substance and Food Interactions

Non-medicinal substances also carry restrictions: Cigarette smoking is a specific restriction for women over 35 due to serious cardiovascular risk, and grapefruit juice intake is documented to potentially increase the estrogen component's exposure.

Mechanism of Action

How Vexa Works

Vexa's Targeted Enzyme Inhibition

Vexa is a direct inhibitor that acts on the activated Factor X (FXa) enzyme. By binding specifically to the active site of this enzyme, Vexa physically halts a critical step in the common pathway of the coagulation cascade. This interaction prevents FXa from catalyzing the conversion of prothrombin to thrombin, which results in a reduction in the rate of thrombin generation within the blood plasma.


Modulating the Blood Clotting Pathway

Operating within the circulatory system, Vexa modifies early molecular steps in the common pathway, suppressing signaling sequences that lead to the formation of a fibrin clot. This targeted pathway interference engages mechanisms that modulate the overall clotting process. The ensuing modulation of blood hemostasis is the primary system-level physiological consequence of Vexa's mechanism, altering clotting factor function throughout the vascular system.

Dosage and Administration Information

Vexa is administered exclusively by the oral route, with the dosage schedule strictly defining its usage pattern. The standard regimen requires taking one tablet daily over a continuous 28-day cycle. This cycle comprises 24 consecutive days of active combined hormone tablets, containing Drospirenone 3 mg and Ethinyl Estradiol 0.02 mg, followed immediately by 4 consecutive days of inert (non-hormonal) tablets. To ensure procedural consistency, administration must occur at the same time every day, regardless of meal timing, though it is often suggested to take the tablet after the evening meal or at bedtime.

The medication's proper use is governed by a mandatory sequence; tablets must be taken exactly in the order indicated on the blister packaging. When initiating treatment, a new user may employ either a Day 1 Start or a Sunday Start method. A critical procedural condition requires the use of a non-hormonal back-up contraceptive method during the first seven consecutive days of administration in the first cycle. For long-term use, a new 28-day pack must be started immediately following the last inert tablet.

Regarding population-specific use, Vexa is indicated for female adolescents of reproductive potential after the onset of menarche. Certain clinical limitations exist, advising against the use of this product in women with renal impairment or adrenal insufficiency. Correct and consistent administration of the daily tablet is the core procedural constraint, as adherence is directly linked to the expected effectiveness. Detailed, week-specific instructions are available to address the protocol for a missed active tablet.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Vexa

Evidence for Use in Pregnancy Prevention (Contraception)

The evidence framework for the contraception indication was evaluated primarily through large-scale, multi-center trials. These were generally open-label studies conducted in healthy females of reproductive potential. Studies monitored a key metric called the Pearl Index, which measures the rate of pregnancy per 100 women using the product for one year. In these large research settings, studies that monitored the Pearl Index (pregnancy rate) described measurements in populations observed during one year of consistent use. Research also examined patterns of continuation and adherence rates among study participants.

Evidence for Use in Premenstrual Dysphoric Disorder (PMDD)

Research exploring Vexa for PMDD involved short-term, randomized, double-blind, placebo-controlled trials (RCTs), comparing the product against an inactive pill (placebo). Researchers examined outcomes related to physical discomfort and changes in specific PMDD symptoms, such as irritability, mood swings, and anxiety, using validated daily rating scales. Studies monitored and described patterns of change in these symptoms over the course of the research. The data described a significant placebo response in the trials, where the control group also reported measured changes in symptom scores.

Evidence for Use in Moderate Acne Vulgaris

The research framework for the moderate acne indication also involved controlled clinical trials conducted over an intermediate period (six cycles). These studies focused on females with moderate facial acne who were also utilizing contraception. Research examined outcomes linked to inflammatory or irritative states, focusing on objective measurements in the count of both inflammatory lesions and non-inflammatory lesions. Studies reported how lesion counts evolved in the observed populations during the study duration.

What is Still Uncertain About Vexa: Research Gaps and Limitations

Follow-up durations were limited in the controlled settings for the symptomatic indications; PMDD effects were evaluated over only three cycles, meaning long-term effects are not fully established. The symptomatic indications showed a significant placebo effect in the controlled studies, which introduced variability. Furthermore, the results apply only to the populations studied in the primary trials, such as those with moderate acne who were already utilizing contraception.

Key Studies & References Effect of ethinyl estradiol/drospirenone (24/4 regimen) on functional impairment in women with premenstrual dysphoric disorder

Frequently Asked Questions (FAQ)

Common questions about Vexa (FAQ)


Q: How quickly should I expect to see an improvement after starting Vexa?

Studies and official information indicate that Vexa's full effect may not be immediate. For pregnancy prevention, a non-hormonal back-up method is required for the first seven days of the first cycle. For other approved uses like PMDD or moderate acne, clinical trials evaluated effectiveness over multiple treatment cycles, suggesting that the full effects may take longer than one cycle to be fully appreciated.


Q: Is Vexa generally considered safe for long-term use?

The official product information states that clinical trials for symptomatic uses (like PMDD and acne) were short-term (e.g., three to six cycles), meaning long-term effects are not fully established for those specific indications. For contraception, ongoing medical evaluation is commonly required, particularly as risk factors such as age and smoking may change over extended use.


Q: Is it normal to feel a mild headache when first starting Vexa?

According to the official product information, headache is listed as a common adverse reaction that has been reported during the use of Vexa. Official labeling states that new, recurrent, persistent, or severe headaches warrant a medical evaluation.


Q: How important is it to take Vexa at the exact same time every day?

Taking the tablet consistently at the same time every day is considered important for maintaining effectiveness for pregnancy prevention. Official documents link this consistent administration to the expected contraceptive efficacy.


Q: Does Vexa cause weight gain or weight loss?

Weight changes, including weight gain, have been reported as potential side effects in authoritative patient information for this class of medicine. However, weight changes are not typically listed among the most common adverse reactions in clinical trials for this specific combination.


Q: Are there any known long-term side effects that appear after years of use?

The official labeling carries Boxed Warnings regarding serious cardiovascular risks, such as blood clots, stroke, and heart attack, which are associated with the use of combination oral contraceptives. These risks are emphasized when combined with other risk factors like age and smoking over extended use.


Q: What should I do if I miss a dose of Vexa?

Specific, week-dependent instructions are provided in the patient information to address missed active tablets. The advice for missing one tablet differs from missing two or more, and often requires the temporary use of back-up contraception.


Q: What signs of a serious side effect, like liver problems, should I watch out for?

Signs of potentially serious liver problems reported include yellowing of the skin or eyes (jaundice), severe fatigue, and pain or tenderness in the abdomen. Liver function tests are often monitored while taking this medicine.


Q: What should I do if I experience mild stomach upset from Vexa?

Gastrointestinal disturbances like diarrhea are reported as common side effects. If severe vomiting or diarrhea occurs within 3 to 4 hours of taking an active tablet, official guidance suggests treating the situation as a missed dose and following the instructions for a missed tablet.


Q: Does Vexa help with other related symptoms besides the main one?

Vexa is formally indicated for three specific uses in women who choose an oral contraceptive: pregnancy prevention, treatment of symptoms of Premenstrual Dysphoric Disorder (PMDD), and treatment of moderate acne vulgaris.


Q: Does Vexa affect my sleep patterns?

Official safety data lists insomnia (difficulty sleeping) as a common adverse reaction reported during the use of Vexa.


Q: Is Vexa similar to hormone replacement therapy (HRT)?

Vexa is not classified as Hormone Replacement Therapy (HRT). It is an oral contraceptive indicated for females of reproductive potential for pregnancy prevention and other specified conditions. Official information states it is not indicated for use in post-menopausal women, which is the population HRT typically targets.


Q: Can men use Vexa for any medical purpose?

Regulatory documents indicate that Vexa is only formally approved for use by females of reproductive potential. The medication is not labeled or approved for any medical purpose in men.


Q: Does Vexa affect blood pressure?

Official labeling states that an increase in blood pressure has been reported in women taking Combined Oral Contraceptives. Women with well-controlled hypertension should be monitored, and those with uncontrolled hypertension should not use Vexa.


Q: Are there certain foods or supplements that should be avoided while taking Vexa?

Co-administration with the herbal product St. John's Wort is specifically restricted due to the risk of reducing Vexa's effectiveness. Additionally, the intake of grapefruit juice is documented as potentially increasing the exposure of the estrogen component.


Q: Does Vexa interact with alcohol?

Official labeling does not list alcohol as a substance to be avoided like smoking or grapefruit juice. However, some authoritative drug information notes that ethanol (alcohol) has a minor interaction with the ethinyl estradiol component, which may require monitoring for side effects.


Q: How does the mechanism of Vexa differ from older treatments for this condition?

Vexa contains the progestin drospirenone, which has a different chemical structure than older progestins. This ingredient possesses anti-mineralocorticoid and anti-androgenic properties, which are specific attributes that distinguish it from many older combination oral contraceptive products.


Q: What is the risk of having an allergic reaction to Vexa?

Official regulatory documents state that Vexa is contraindicated in patients who have a known hypersensitivity or allergy to any of its components or any part of the formulation. This is a standard caution for all medications.


Q: What information should I share with my doctor before starting Vexa?

Patients should inform their doctor about all existing medical conditions and history, including a history of blood clots, high blood pressure, diabetes with vascular disease, liver or kidney problems, or a history of breast cancer. Sharing this information helps determine if the medication is appropriate based on official contraindications.


Q: Are there any known interactions between Vexa and herbal supplements?

Yes, co-administration with the herbal product St. John's Wort is specifically documented to reduce the plasma concentration of Vexa's hormones, which risks reducing contraceptive effectiveness.


Q: What happens if I accidentally take two doses of Vexa in one day?

In cases where more than the prescribed dose is taken, symptoms reported have included nausea, vomiting, and withdrawal bleeding.


Q: Does Vexa have any effect on mood or anxiety?

Official product information states that women with a history of depression should be monitored and discontinuation should be considered if depression recurs to a serious degree. Mood changes, nervousness, and anxiety have also been reported as adverse reactions.


Q: What happens in the brain that Vexa is trying to correct?

Vexa achieves its primary action by modulating the hormonal signals in the body that regulate the monthly reproductive cycle, which is centrally controlled. This modulation primarily results in the Inhibition of Ovulation.


Q: Does Vexa make the treated condition go away completely or just manage symptoms?

Vexa is primarily used to prevent pregnancy and to manage the symptoms associated with PMDD and moderate acne vulgaris. It is generally described as a symptomatic management tool rather than a permanent cure for these conditions.


Q: If Vexa is stopped, do the original symptoms return immediately?

If Vexa is discontinued, the effects on the hormonal cycle and related symptoms will stop, and the individual's pre-existing menstrual patterns or symptoms may resume.


Q: Does Vexa interact with caffeine?

Some authoritative drug information indicates that the ethinyl estradiol component may increase the blood levels of caffeine. This could potentially increase the risk or severity of caffeine-related side effects such as nausea or nervousness.


Q: Is the severity of side effects related to the dose of Vexa?

For this fixed-dose product, the severity of common side effects is not typically detailed as dose-dependent in the official labeling. However, the risk of certain serious cardiovascular effects is generally associated with the concentration of hormones in combined oral contraceptives.


How should Vexa be stored and disposed of?

Vexa (Drospirenone and Ethinyl Estradiol) must be stored according to official regulatory labeling to maintain its stability and effectiveness.


Storage Conditions and Requirements

Vexa tablets are required to be stored at controlled room temperature, defined as 20°C to 25°C (68°F to 77°F). Brief temperature excursions are permitted between 15°C and 30°C (59°F and 86°F).

  • Container: The product must remain in its original container/blister pack and be stored in a cool, dry place.
  • Safety: The medication must be kept out of the reach of children and pets.

Disposal Instructions

Unused or expired Vexa should be safely disposed of using a drug take-back program or mail-back option, which is the preferred method. If these programs are not available, the medication can be discarded in the household trash. This involves mixing the tablets with an undesirable substance, such as dirt or used coffee grounds, and sealing the mixture in a container before placing it in the trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vexa found in:

A-Z Index: